Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate SARS-CoV-2 Infection
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess
the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2
infection. The total study duration is up to 28 days.